Skip Navigation

European Journal of Heart Failure 2001 3(1):117-124; doi:10.1016/S1388-9842(00)00145-8
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thackray, S. D.R.
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thackray, S. D.R.
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure

Simon D.R. Thackray, Klaus K.A. Witte, Aleem Khand, Anita Dunn, Andrew L. Clark and John G.F. Cleland*

Academic Cardiology, University of Hull, Castle Hill Hospital Castle Road, Kingston upon Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44-1482-624087; fax: +44-1482-624085. E-mail address: j.g.cleland{at}medschool.hull.ac.uk (J.G. Cleland).


  Abstract

This article continues a series of reports summarising recent research developments pertinent to the topic of heart failure. This is a summary of presentations made at scientific sessions of the American Heart Association in November 2000. Clinical studies of particular interest to people caring for patients with heart failure include Val-HeFT, AMIOVIRT and V-MAC. New data from β-blockers trials are reviewed, highlights from some important developments in post-infarction care, including MIRACL and FLORIDA, discussed and results of some early studies of gene therapy reported.

Key Words: Val-HeFT • AMIOVIRT • V-MAC • Post-infarction care


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
A. P. Coletta and J. G.F. Cleland
Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology -- WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME
Eur J Heart Fail, December 1, 2001; 3(6): 747 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
E. Erdmann, P. Lechat, P. Verkenne, and H. Wiemann
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure
Eur J Heart Fail, August 1, 2001; 3(4): 469 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Louis, J. G.F. Cleland, S. Crabbe, S. Ford, S. Thackray, T. Houghton, and A. Clark
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
Eur J Heart Fail, June 1, 2001; 3(3): 381 - 387.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.